Medicines for Malaria Venture (MMV), Route de Pre-Bois 20, 1215, Meyrin, Switzerland.
Malar J. 2024 Sep 6;23(1):270. doi: 10.1186/s12936-024-05100-z.
Post-discharge malaria chemoprevention (PDMC) is an intervention aimed at reducing morbidity and mortality in patients hospitalized with severe anaemia, with its effectiveness established in several clinical trials. The aim of this study was to better understand factors that would influence the scale up of this intervention, and to identify preferences for two delivery mechanisms, facility-based or community-based.
Forty-six qualitative individual interviews were conducted in five sub-Saharan countries amongst malaria key opinion leaders and national decision makers. Findings were analysed following a thematic inductive approach.
Half of participants were familiar with PDMC, with a satisfactory understanding of the intervention. Although PDMC was perceived as beneficial by most respondents, there was some unclarity on the target population. Both delivery approaches were perceived as valuable and potentially complementary. From an adoption perspective, relevant evidence generation, favorable policy environment, and committed funding were identified as key elements for the scale up of PDMC.
The findings suggest that although PDMC was perceived as a relevant tool to prevent malaria, further clarification was needed in terms of the relevant patient population, delivery mechanisms, and more evidence should be generated from implementation research to ensure policy adoption and funding.
出院后疟疾化学预防(PDMC)是一种旨在降低因严重贫血住院患者发病率和死亡率的干预措施,其有效性已在多项临床试验中得到证实。本研究旨在更好地了解影响该干预措施扩大规模的因素,并确定对两种实施机制(医疗机构为基础或社区为基础)的偏好。
在撒哈拉以南的五个国家,对疟疾主要意见领袖和国家决策者进行了 46 次定性个人访谈。采用主题归纳法对研究结果进行了分析。
半数参与者熟悉 PDMC,并对该干预措施有满意的了解。尽管大多数受访者认为 PDMC 有益,但对目标人群仍存在一些不明确性。两种实施方法都被认为具有价值且具有互补性。从采用的角度来看,相关的证据生成、有利的政策环境和承诺的资金被确定为 PDMC 扩大规模的关键因素。
研究结果表明,尽管 PDMC 被认为是预防疟疾的一种相关工具,但在相关患者人群、实施机制方面仍需要进一步澄清,应从实施研究中生成更多证据,以确保政策采纳和资金投入。